UNSPSC 51181929: Ganirelix acetate

This classification denotes a gonadotropin releasing hormone inhibitor with the molecular formula C80H113CLN18O13.2C2H4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 56U7906FQW. European Medicines Agency schedules ganirelix acetate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25637. The term ganirelix acetate is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule ganirelix acetate under HS 29371900 and SITC 54154.

Ganirelix acetate bears US NLM identifiers UMLS ID C0872894 and NCI Concept Code C61774. SMILES: As of Q4 2014, GANIRELIX ACETATE remains US FDA's Preferred Term for this commodity.

UNSPSC 51181929 Ganirelix acetate, a Commodity code, encompasses generic pharmaceutical products supplied through cooperative purchasing alliances to state and local government healthcare facilities. State and local governments buy ganirelix acetate and related generic multi-source pharmaceuticals through established wholesale distribution channels, with vendors supplying products by National Drug Code (NDC), SKU, UPC, and specified packaging and strength configurations to serve hospitals, clinics, and other public healthcare operations.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the active issuing body identified in recent solicitations. MMCAP issued a Request for Proposal (S1070000015802) on January 20, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products across participating state and local government facilities, including Oregon, with proposals due March 26, 2026. Vendors must maintain contractual relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, or Morris & Dickson Co., LLC), certify compliance with current Good Manufacturing Practices and the Drug Supply Chain Security Act, and meet comprehensive insurance requirements including commercial general liability of $5,000,000 per occurrence and network security and privacy liability of $2,000,000. Evaluation emphasizes price competitiveness (75 percent) and adherence to pricing format requirements, with awarded vendors effective July 1, 2026, for a two-year initial term with optional extensions. The solicitation does not specify dollar values but imposes a 3 percent administrative fee on all contract purchases and performance penalties of $200 to $1,500 per violation for issues such as late reporting or missed onboarding timelines.